Zopump LS 75mg/20mg Capsule is a combination pharmaceutical formulation containing Levosulpiride 75mg and Rabeprazole 20mg, indicated for the management of gastroesophageal reflux disease (GERD), functional dyspepsia, and related upper gastrointestinal motility disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic effects by enhancing gastric emptying and improving esophageal motility, thereby alleviating symptoms such as nausea, vomiting, bloating, and abdominal discomfort. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in the parietal cells of the stomach, promoting mucosal healing and reducing acid-related irritation. The synergistic action of these agents addresses both the motility dysfunction and acid hypersecretion components of gastrointestinal disorders, providing comprehensive symptomatic relief. Zopump LS is typically administered orally once daily before meals, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with hypersensitivity to either component, and monitoring is recommended in individuals with hepatic or renal impairment. Common adverse effects may include headache, dizziness, and mild gastrointestinal disturbances. This combination therapy should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.